Compare CVS Health Corp (CVS) vs IONQ Inc (IONQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CVS Health Corp vs IONQ Inc — how do they compare? CVS Health Corp trades at $85.46 (market cap $112.29B), while IONQ Inc trades at $40.05 (market cap $15.98B). The key difference: CVS Health Corp is far larger — about 7× IONQ Inc's market cap, and CVS Health Corp pays a 3.03% dividend while IONQ Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold CVS Health Corp for 83 Days and IONQ Inc for 33 Days on average.
| CVS | IONQ | |
|---|---|---|
Market Cap | $112.29B | $15.98B |
Volume | 7,763,676 | 22,848,240 |
Sector | Health | Technology |
52-Week High | $110.60 | $82.09 |
52-Week Low | $70.08 | $26.59 |
Typical Hold Time | 83 Days | 33 Days |
Enterprise Value | $174.64B | $13.92B |
Dividend Yield | 3.03% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $87.95, up 1.76% with strong analyst support (85% buy ratings) and a $111.20 consensus price target suggesting 26% upside. Recent quarterly earnings consistently beat expectations, with Q2 2026 EPS of $2.58 surpassing the $1.85 estimate. Revenue growth remains solid at $402.07 billion for 2025, though net margins compressed to 1.18%. Technical indicators show a bullish overall signal with support at $87 and resistance at $89.
The outlook remains positive given CVS's dominant market position and Medicare expansion plans, but investors face risks from reimbursement pressures and ongoing legal investigations. Earnings growth and successful execution of healthcare services integration represent the primary catalysts for continued stock appreciation.
IONQ trades at $41.34, down 4.5% today, with a mixed technical signal leaning bullish overall. The company reported revenue of $130.02M in 2025 but a net loss of $510.38M, reflecting high growth spending. Recent news highlights strong analyst backing, including Bank of America's Buy rating and $60 target, citing IonQ's trapped-ion quantum computing technology and partnerships.
Outlook: IonQ offers high growth potential in quantum computing, supported by bullish analyst targets averaging $62.75. Risks include persistent losses, cash burn, and intense competition. Investors should weigh the long-term disruptive potential against current profitability challenges and valuation premiums.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →About IONQ Inc
IonQ is a leader in quantum computing, developing world-class quantum systems. Its technology aims to solve complex problems across finance, healthcare, and materials science that are beyond classical computers.
Read more on IONQ →
